PD 2024Alternative Names: PD-2024
Latest Information Update: 21 Jul 2016
At a glance
- Originator P2D Bioscience
- Class Anti-inflammatories; Antidementias
- Mechanism of Action RNA interference; Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Dementia
Most Recent Events
- 21 Jul 2016 Preclinical trials in Alzheimer's disease in USA (PO)
- 21 Jul 2016 Preclinical trials in Dementia in USA (PO)